B
Bowen Carrie A
Researcher at Sunovion
Publications - 7
Citations - 69
Bowen Carrie A is an academic researcher from Sunovion. The author has contributed to research in topics: Enzyme & Gabapentin. The author has an hindex of 4, co-authored 7 publications receiving 67 citations.
Papers
More filters
Journal ArticleDOI
Structural, Kinetic, and Pharmacodynamic Mechanisms of d-Amino Acid Oxidase Inhibition by Small Molecules
Seth C. Hopkins,Michelle L. R. Heffernan,Lakshmi D. Saraswat,Bowen Carrie A,L. Melnick,Larry W. Hardy,M. A. Orsini,Mike Allen,Patrick Koch,Kerry L. Spear,R. J. Foglesong,Mustapha Soukri,Milan Chytil,Q. K. Fang,Steven Jones,Mark A. Varney,A. Panatier,Stéphane H. R. Oliet,Loredano Pollegioni,Luciano Piubelli,Gianluca Molla,Marco Nardini,Thomas H. Large +22 more
TL;DR: DAAO inhibition increased the spatiotemporal influence of glial-derived d-serine, suggesting localized effects on neuronal circuits where DAAO can exert a neuromodulatory role.
Journal ArticleDOI
Pharmacodynamic Effects of a d-Amino Acid Oxidase Inhibitor Indicate a Spinal Site of Action in Rat Models of Neuropathic Pain
Seth C. Hopkins,Fei-Yue Zhao,Bowen Carrie A,Xin Fang,Haifeng Wei,Michelle L. R. Heffernan,Kerry L. Spear,David Spanswick,Mark A. Varney,Thomas H. Large +9 more
TL;DR: Results indicate that inhibition of DAAO in peripheral afferent spinal circuits reduced spontaneous neuronal activity to attenuate pain-related behaviors in rat models of neuropathic and inflammatory pain.
Patent
Modulators of opioid receptors and methods of use thereof
TL;DR: In this paper, the authors present compounds and methods of synthesis thereof for the treatment, prevention, and management of various disorders, such as pain, neurological disorders, psychiatric disorders, and neuromuscular disorders.
Patent
Compounds and compositions and uses thereof
TL;DR: In this paper, compounds of formula (I): and pharmaceutical compositions containing such compounds were disclosed Methods of treating neurological or psychiatric disease and disorders in a subject in need were also disclosed, and the results of these methods were presented.
Patent
Isochroman compounds and uses thereof
TL;DR: In this paper, the authors described the composition of Formula I compounds, as well as pharmaceutical compositions containing such compounds, and methods of treating neurological or psychiatric diseases and disorders in a subject in need.